While standard adjuvant chemotherapy for osteosarcoma (OS) is well established, survival rates for adolescent and young adult (AYA) patients have hit a plateau. To break through this ceiling, the field is rapidly pivoting toward the tumor microenvironment (TME) and novel targeted agents. This educational session bridges cutting-edge translational science with clinical application, highlighting the major role of the TME—specifically macrophage activation via immunotherapeutic agents like mifamurtide—alongside the next wave of therapeutics, including Tyrosine Kinase Inhibitors (TKIs) and CAR-T cell therapies.

While standard adjuvant chemotherapy for osteosarcoma (OS) is well established, survival rates for adolescent and young adult (AYA) patients have hit a plateau. To break through this ceiling, the field is rapidly pivoting toward the tumor microenvironment (TME) and novel targeted agents. This educational session bridges cutting-edge translational science with clinical application, highlighting the major role of the TME—specifically macrophage activation via immunotherapeutic agents like mifamurtide—alongside the next wave of therapeutics, including Tyrosine Kinase Inhibitors (TKIs) and CAR-T cell therapies.

Beyond Chemotherapy: Unlocking Therapeutic Strategies in Osteosarcoma

📅 Date: December 3, 2026 🕒 Time: 14:00 CET | 08:00 EST 📍 Format: Live Interactive Webinar (Two Parts)

REGISTRATION

Why Attend?

This educational webinar bridges cutting-edge translational science with clinical application in osteosarcoma. Join world-renowned experts as they evaluate the latest European and North American data on tumor microenvironment targeting, TKIs, and cellular immunotherapies for refractory and metastatic disease.

Target Audience: Paediatric oncologists, fellows, translational researchers, and multidisciplinary sarcoma specialists.

The Programme

Part I: Scientific Panel – Current Research & Clinical Insights

Focused discussions on breaking through survival plateaus by targeting the tumor microenvironment, novel TKIs, and emerging cellular immunotherapies.

  • Co-Chairs / Moderators: Prof. Rejin Kebudi (American Hospital & Istanbul University Oncology Institute, Türkiye) & Prof. Hans Merks (Princess Máxima Center for Pediatric Oncology, Netherlands)

  • Introduction & Session Overview (14:00 – 14:05) Moderators: Prof. Rejin Kebudi & Prof. Hans Merks

  • Talk 1: Macrophage Activation as a therapeutic strategy in Osteosarcoma: Mechanism and clinical potential. (14:05 – 14:25)

    • Speaker: Dr. Emanuela Palmerini (University of Miami & Sylvester Comprehensive Cancer Center, USA / Italy)

    • Dr. Palmerini is a renowned faculty member in Sarcoma and Phase I Programs, specializing in novel therapeutics and clinical management of bone sarcomas.

  • Talk 2: Unlocking New Pathways in Europe: Recent Clinical Trials and Novel Therapeutic Strategies for Osteosarcoma (14:25 – 14:45)

    • Speaker: Dr. Nathalie Gaspar (Gustave Roussy Cancer Campus, France)

    • Dr. Gaspar is Head of the Adolescent and Young Adult (AYA) unit and Chair of the Institute SPIAJA AYA Programme, leading major initiatives in paediatric and AYA sarcoma trial design.

  • Talk 3: Targeting Osteosarcoma in North America: COG Trials and Emerging Data on TKIs, ADCs, and Novel Agents (14:45 – 15:05)

    • Speaker: Dr. Katherine Janeway (Dana-Farber/Boston Children’s Cancer and Blood Disorders Center & Harvard Medical School, USA)

    • Dr. Janeway serves as Director of Clinical Genomics at Dana-Farber, pioneering precision medicine, translational genomics, and targeted therapy trials in paediatric solid tumours.

Part II: Interactive Panel & Multi-Stakeholder Dialogue (15:05 – 15:30)

A dedicated interactive Q&A and roundtable discussion bridging translational science and clinical application across European and North American paradigms.

  • Moderators: Prof. Rejin Kebudi & Prof. Hans Merks

  • Featured Panelists: All session speakers (Dr. Emanuela Palmerini, Dr. Nathalie Gaspar, and Dr. Katherine Janeway) alongside audience participants.

Together, let’s unlock novel therapeutic strategies to transform outcomes for adolescent and young adult osteosarcoma patients worldwide.

We look forward to your participation.

Organized by: The International Society of Paediatric Oncology (SIOP)

This is an independent educational activity supported by an unrestricted educational grant from Esteve.

The scientific programme and content are developed independently by the scientific committee without influence from Esteve.

REGISTRATION